Watson Pharmaceuticals, Inc. confirmed that Momenta Pharmaceuticals, Inc. and Sandoz Inc. have filed suit against Amphastar Pharmaceuticals, Inc. and Watson on September 21, 2011 in the United States District Court for the District of Massachusetts. The suit alleges that Amphastar's Enoxaparin Sodium Injection product, which Watson has the exclusive right to distribute in the US retail pharmacy channel, infringes Momenta's US Patent Nos. 7,790,466 and 7,575,886. Enoxaparin Sodium Injection is a generic equivalent to sanofi-aventis' Lovenox.
Watson and Amphastar intend to vigorously defend the claims in the lawsuit. Pursuant to terms of the distribution agreement between Watson and Amphastar, Watson believes it will be fully indemnified by Amphastar for all costs, expenses and damages, if any, incurred in connection with the lawsuit.
Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on urology and women's health.
Amphastar Pharmaceuticals, Inc., established in 1996, is a specialty and generic pharmaceutical company focusing on injectable, inhalation, and other categories of pharmaceutical products.